Nasdaq: APLM

Corporate Presentation

April 2024

apollomicsinc.com

Cautionary Statement

Regarding forward-looking statements

This presentation is for informational purposes only and shall not constitute an offer to purchase, sell or exchange any security, a solicitation of any offer to purchase, sell or exchange any security, or a recommendation or advice regarding any security of Apollomics, Inc. ("we," "us," "our" or the "Company"), nor shall there be any sale of any securities of the Company in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Sales and offers to sell securities of the Company will only be made in accordance with the Securities Act of 1933, as amended (the "Securities Act"), and applicable Securities and Exchange Commission ("SEC") regulations.

This presentation is being delivered on a confidential basis and is intended solely for the information of the persons to whom it is presented. It may not be retained, reproduced or distributed, in whole or in part, by any means (including electronic) without the prior written consent of the Company. By receiving this presentation, you understand and agree that the fact that this meeting has taken place and anything you hear or learn during this meeting are strictly confidential.

This presentation includes statements that constitute "forward-looking statements" within the meaning of the federal securities laws, including Section 27A of the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). All statements, other than statements of present or historical fact included in this presentation, regarding the Company's future financial performance, as well as the Company's strategy, future operations, revenue guidance, projected costs, prospects, plans and objectives of management are forward-looking statements. When used in this presentation, the words "could," "should," "will," "may," "believe," "anticipate," "intend," "estimate," "expect," "project," the negative of such terms and other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain such identifying words. These forward-looking statements are based on management's current expectations and assumptions about future events and are based on currently available information as to the outcome and timing of future events. Apollomics cautions you that these forward-looking statements are subject to numerous risks and uncertainties, most of which are difficult to predict and many of which are beyond the control of Apollomics. In addition, Apollomics cautions you that the forward-looking statements contained in this presentation are subject to unknown risks, uncertainties and other factors, including: (i) the impact of any current or new government regulations in the United States and China affecting Apollomics' operations and the continued listing of Apollomics' securities; (ii) the inability to achieve successful clinical results or to obtain licensing of third-party intellectual property rights for future discovery and development of Apollomics' oncology projects; (iii) the failure to commercialize product candidates and achieve market acceptance of such product candidates;

  1. the failure to protect Apollomics' intellectual property; (v) breaches in data security; (vi) the risk that Apollomics may not be able to maintain effective internal controls; (vii) unfavorable changes to the regulatory environment; and (viii) those risks and uncertainties discussed in the Apollomics' Annual Report on Form 20-F for the year ended December 31, 22, filed with the SEC on April 28, 2023, under the heading "Risk Factors" and the other documents filed, or to be filed, by the Company with the SEC. Other unknown or unpredictable factors also could have material adverse effects on the Company's future results and/or could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements. Should one or more of the risks or uncertainties described in this presentation materialize or should underlying assumptions prove incorrect, actual results and plans could differ materially from those expressed in any forward-looking statements. New risk factors that may affect actual results or outcomes emerge from time to time and it is not possible to predict all such risk factors, nor can Apollomics assess the impact of all such risk factors on its business, or the extent to which any factor or combination of factors may cause actual results to differ materially from those contained in any forward-looking statements.

Forward-looking statements are not guarantees of performance. You should not put undue reliance on these statements, which speak only as of the date hereof. Additional information concerning these and other factors that may impact the operations and projections discussed herein can be found in the reports that Apollomics has filed and will file from time to time with the SEC. These SEC filings are available publicly on the SEC's website at www.sec.gov. Apollomics undertakes no obligation to update publicly any of these forward-looking statements to reflect actual results, new information or future events, changes in assumptions or changes in other factors affecting forward-looking statements, except to the extent required by applicable law. If Apollomics updates one or more forward-looking statements, no inference should be drawn that Apollomics will make additional

updates with respect to those or other forward-looking statements.

This presentation contains discussions of investigational products that are under preclinical or clinical investigation, and which have not yet been approved for marketing by the U.S. Food and Drug Administration

("FDA"). Investigational products are currently limited by Federal law to investigational use, and no representations are made as to their safety or effectiveness for the purposes for which they are being investigated.

This presentation contains references to trademarks and service marks belonging to other entities. Solely for convenience, trademarks and trade names referred to in this prospectus may appear without the ® or

symbols, but such references are not intended to indicate, in any way, that the applicable licensor will not assert, to the fullest extent under applicable law, its rights to these trademarks and trade names. We do not intend our

use or display of other companies' trade names, trademarks or service marks to imply a relationship with, or endorsement or sponsorship of us by, any other companies.

This presentation does not purport to contain all of the information that may be required to evaluate all of the factors that would be relevant to you in considering any potential transaction and you should conduct

your own investigation and analysis. This presentation is for informational purposes and reference only pursuant to your request and is not intended to be, and must not be, taken as the basis for a decision with respect to any

possible transaction. Neither the Company nor any of its affiliates or representatives makes any representation or warranty, expressed or implied, as to the accuracy or completeness of this presentation or any of the information

contained herein, or any other written or oral communication transmitted or made available to you or your affiliates or representatives. The Company and its affiliates or representatives expressly disclaim to the fullest extent

permitted by law any and all liability based, in whole or in part, on the presentation or any information contained herein, or any other written or oral communication transmitted or made available to you or your affiliates or

2

representatives, including, without limitation, with respect to errors therein or omissions therefrom.

This Presentation is not intended to form the basis of any investment decision by you and does not constitute investment, tax or legal advice.

Vebreltinib - A Differentiated cMET Inhibitor Addressing Unmet Need

Significant market

opportunities in NSCLC

combo therapy

Best-in-class

&

First-in-class potential

Regulatory pathway

towards US NDA

  • c-Metdysregulated cancers as monotherapy (~12K U.S. patients in lung and brain tumors alone; many more patients with MET dysregulated tumors in other organs)
  • ~15-50%of NSCLC patients on targeted therapies (EGFR, KRAS, ALK, ROS) progress due to acquired MET amplification - combo therapy market for treatment resistance & first line
  • Best-in-classactivity in Met Exon14 skipping NSCLC patients without co-occurring MET amplification
  • First-in-classpotential for Met Amp+ NSCLC, glioblastoma multiforme (GBM) with Met fusions, and others
    • FDA accepted pooling of SPARTA (global) and KUNPENG (China trial also known as PEARL) studies for MetEx14 skip NSCLC
    • FDA did not require a randomized controlled Phase 3 trial
    • Near term NDA 2025/2026 timeframe

3 3

3 Monotherapy Indications

1st Indication

2nd Indication

3rd Indication

Recurrent

1L metastatic

2L+ NSCLC

GBM with

NSCLC with

with c-Met

PTPRZ1-Met

Met Exon 14

Amplification

Fusions

skipping

Pivotal Phase 2 study- ongoing

Phase 2 Pivotal Study Enrollment Ongoing,

US Regulatory timeline

Target NDA submission 2025/2026

Target NDA submission (US) 2026

Under assessment

Launched in China by Avistone

sNDA Approval (China NMPA)

NDA approved 11/2023

granted to Avistone 4/23/2024

4

NSCLC

NSCLC

r/r GBM

Ex14 Skipping

Amp+

Met-Fusion

Vebreltinib for MetEx14 Skip NSCLC Clinical Regulatory Status

  • Conditionally approved by NMPA in China, Nov 2023
  • FDA meeting July 2023:
    • "FDA acknowledged that Apollomics may have a path towards traditional approval in the context of their current clinical trials. FDA recommended that Apollomics should review their development plan and propose an additional meeting to discuss this approach."
    • "FDA acknowledged that Apollomics proposal to pool data from SPARTA and PEARL appears acceptable; however, given the limitations stated above a final determination will be made upon review of the data submitted to a potential marketing application."
  • FDA meeting Feb 2024: Continue to enroll in 1L MetEx14 NSCLC cohort
  • Plan to have preNDA meeting with FDA after additional patients have had 12 months follow up data

5

cMET Inhibitors Landscape

NSCLC

NSCLC

r/r GBM

Ex14 Skipping

Amp+

Met-Fusion

1

Capmatinib2

Tepotinib3

Savolitinib4

Telisotuzumab5

Amivantamab6

Vebreltinib

(Tabrecta)

(Tepmetko)

(Orpathys)

(Teliso-V)

(Rybrevant)

1L NSCLC with Met

ORR

66%

68%

57%

46%

N

(n=71)

(N=60)

(N=164)

(N=28)

N/A

57%

exon 14 skipping

mDoR

16.5 mos

16.6 mos

40% DoR≥12 mos

5.6 mos

2L+ NSCLC with Met

ORR

61%

44%

45%

41%

N

(n=36)

(N=100)

(N=149)

(N=42)

N/A

47%

exon 14 skipping

mDoR

16.7 mos

9.7 mos

36% DoR≥12 mos

5.6 mos

2L+ cMet Amplified

ORR

Ongoing

12% GCN 6-10

29%

N/A

N/A

Pursuing

NSCLC de novo

N

29% GCN >10

(N=17)

Unpublished

Recurrent GBM with PTPRZ1 Met

48% reduction in

risk of death in OS;

N/A

N/A

N/A

N/A

N/A

fusions

mOS 6.31 vs 3.38

mos

35% Met high

2L+ cMet

ORR

N/A

N/A

N/A

N/A

9.0 mos

N/A

overexpressing NSCLC

mDoR

23% Met inter

7.2 mos

1. Data from KUNPENG and SPARTA trial for MetEx14 skip NSCLC

2. Capmatinb Package Inset from Full Approval; Wolf et al 2020

3. Tepotinib package insert from Full Approval; Xuining Le et al 2023

4. Savolitinib data from Zhu et al Cancers 2023

5. LUMINOSITY trial for monotherapy; Abbvie Press Release Nov 2023

6

6. CHRYSALIS study Leighl et. al. ESMO 2023

NSCLC

NSCLC

r/r GBM

Limitation in Capmatinib's Treatment in MetEx14 Skip NSCLC

Ex14 Skipping

Amp+

Met-Fusion

Especially in MetEx14 Skip NSCLC patients without overlapping Met Amp (GCN<4)

  • Capmatinib Accelerated Approval (N=97)
    • 1L ORR 68% (n=28)
    • 2L+ ORR 41% (n=69)
    • 82 patients with GCN data available:
      • ORR 18% in patients with GCN<4 (no co-occurring MET amplification)
  • Capmatinib Regular Approval (N=160)
    • 1L ORR 68% (n=60)
    • 2L+ ORR 44% (n=100)
    • No additional efficacy data by GCN subgroup Available

Unmet Medical Need:

Need more effective treatment for patients with MetEx14 skip NSCLC and no co-occurring MET amplification (GCN<4)

Overall Response Rate (ORR)

70%

60%

50%

40%

30%

20%

10%

0%

Capmatinib ORR in NSCLC with MetEx14 Skip by GCN

count in the 82 patients with GCN

57% 60%

38%

18%

n=22

n=47

n=35

n=15

GCN<4

GCN<6

GCN >=6

GCN>=10

7

Vebreltinib

MetEx14 skip NSCLC Study Populations by GCN Subgroups

NSCLC

NSCLC

r/r GBM

Ex14 Skipping

Amp+

Met-Fusion

In patients with available GCN data in SPARTA & KUNPENG studies

Vebreltinib Dataset Resembles Real World

Patient Samples

Patient Distribution by GCN (%)

Vebreltinib Efficacious In All GCN Subgroups

Regardless of MET Amplification

ORR in GCN Subgroups

100%

100%

90%

Vebreltinib (n=91)

capmatinib (n=82)

cBioportal (n=157)

AACR Genie (n=421)

26.8%

94.5% patients with GCN <4

89.2%

83.6%

Overall Response Rate (ORR)

80%

67%

69%

70%

57%

60%

50%

38%

40%

30%

18%

20%

0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100%

GCN<4 4≤GCN<6 GCN >=6

  • GCN<4 no over-lapping MET Amplification
  • GCN ≥6 over-lapping MET Amplification

10%

n=22

n=86

n=47 n=90

n=35 n=1

0%

GCN<4

GCN<6

GCN >=6

Capmatinib

(N=83, GEOMETRY) (n=91, SPARTA+KUNPENG)

8

Capmatinib data source: Summary basis for approval, page 78.

MexEx14 Skip NSCLC Patients In

SPARTA (Global Study) & KUNPENG (China Study)

NSCLC

NSCLC

r/r GBM

Ex14 Skipping

Amp+

Met-Fusion

SPARTA

KUNPENG (Pearl II)

Multicohort Open-Label Phase II study

Primary endpoint ORR based on RECIST 1.1, supported by DOR

Regions

US, Canada, EU,

China

APAC (ex-China)

Sponsor

Apollomics

Avistone

MET exon 14 skipping NSCLC: include 1L & 2L+ patients

identified by NGS, unresectable or metastatic disease

Treatment: vebreltinib 200 mg BID

1L patients (efficacy set for US NDA)

N=36

N=35

GCN<4:

n=28; ORR 64.3%

n=28; ORR 71.4%

Median age, years (range)

75.0 (53, 86)

71.0 (53, 90)

Female (%)

58.3%

48.6%

Non-smokers

52.8%

65.7%

ECOG 0

33.3%

14.3%

ECOG 1

66.7%

85.7%

Histology at diagnosis: % Adenoma

88.9%

88.6%

9

Notes: KUNPENG - ESMO 2023 Poster; SPARTA - Internal Data

MetEx14 Skip NSCLC

NSCLC

NSCLC

r/r GBM

Ex14 Skipping

Amp+

Met-Fusion

1L NSCLC Patients

2L+ NSCLC Patients

MetEx14 Skip NSCLC

SPARTA-II

Pearl-II

Combined

Capmatinib

SPARTA-II*

Pearl-II

Combined

Capmatinib

CCAS[1]

(KUNPENG)

(KUNPENG)

(N=36)

(N=35)

(N=71)

(N = 60)

(N=19)

(N=17)

(N=36)

(N = 100)

Confirmed ORR

55.6%

77.1%

66.2%

68%

52.6%

70.6%

61.1%

44%

95% CI

(38.1, 72.1)

(59.9, 89.6)

(54.0, 77.0)

(55, 80)

(28.9, 75.6)

(44.0, 89.7)

(43.5, 76.9)

(34, 54)

mDOR (Months)

11.2

17.1

16.5

16.6

10.6

16.7

16.7

9.7

95% CI

6.0, NE

9.2, NE

9.2, 23.0

(8.4, 22.1)

1.1, NE

3.7, NE

5.4, NE

(5.6, 13.0)

DOR >= 12 Months

35.8%

60.5%

52.2%

49%

30.9%

61.4%

53.8%

36%

DCR (%)

91.7%

97.1%

94.4%

73.7%

94.1%

83.3%

95% CI

(77.5, 98.2)

(85.1, 99.9)

(86.2, 98.4)

(48.8, 90.9)

(71.3, 99.9)

(67.2, 93.6)

  1. Patients who first dosed prior to 2023-05-31 in SPARTA-II CCAS population and patients who first dosed prior to 2021-12-31 in Pearl-II are included. * Patients with last IO use < 90 days in SPARTA-II are excluded.
    Based on data available up to 2023-10-26
    Patients with central tissue NGS confirmed MetEx14 Skip NSCLC NE = Not estimable yet

10

Attachments

  • Original Link
  • Original Document
  • Permalink

Disclaimer

Apollomics Inc. published this content on 25 April 2024 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 25 April 2024 12:45:05 UTC.